Related Experiment Videos
[Retinoid PUVA (RePUVA): systemic combination therapy in psoriasis].
Zeitschrift Fur Hautkrankheiten
|July 15, 1978
Summary
RePUVA, a combination of retinoid and PUVA therapy, effectively treats psoriasis, even in patients resistant to standard PUVA. This approach reduces treatment duration and UVA exposure, minimizing potential long-term risks.
Area of Science:
- Dermatology
- Phototherapy
- Pharmacology
Context:
- Psoriasis is a chronic inflammatory skin condition.
- Standard PUVA (psoralen plus ultraviolet A) therapy is a common treatment.
- Some patients exhibit resistance to conventional PUVA therapy.
Purpose:
- To evaluate the efficacy of RePUVA, a combined retinoid and PUVA treatment, for psoriasis.
- To assess the optimal administration schedule for the retinoid component.
- To compare RePUVA outcomes with standard PUVA treatment, particularly in PUVA-resistant cases.
Summary:
- RePUVA involves oral retinoid administration (50-75 mg daily) combined with systemic PUVA.
- An overall response rate of 73% was observed, with 82.6% response in non-PUVA-resistant patients.
- The most successful RePUVA schedule involved administering the retinoid before and concurrently with PUVA, requiring fewer sessions and lower UVA doses.
Impact:
- RePUVA demonstrates significant efficacy in treating psoriasis, including in patients resistant to standard PUVA.
- This therapeutic approach may reduce treatment duration and total UVA dosage, thereby mitigating potential long-term side effects associated with PUVA.
- Findings suggest RePUVA as a promising alternative or adjunct therapy for psoriasis management.